Chardan Capital Markets downgraded Clovis Oncology (NASDAQ: CLVS) from Neutral to Sell with a price target of $36.00.Analyst Dr. Madhu ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE